Comparing two chemotherapy regimens for stem cell mobilization in lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of a combination therapy involving etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma. A total of 99 patients will be randomly assigned to receive either this experimental regimen or a disease-specific chemotherapy regimen. The primary goal is to determine the proportion of patients achieving the ideal collection of CD34+ cells after a single collection. The study will also monitor adverse reactions and the overall effectiveness of both treatment approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with non-Hodgkin's lymphoma before enrollment.
* Indication for autologous stem cell transplantation (ASCT).
* Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
* Achieved complete remission after multiple courses of chemotherapy.
* Life expectancy ≥ 3 months.
* Subjects must be able to understand the protocol and sign the informed consent.

Exclusion Criteria:

* Cardiac function class II or higher or cardiac ejection fraction \< 40%.
* Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN).
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) more than three times the upper limit of normal (ULN).
* Serum creatinine clearance rate ≤ 50%.
* Patients with active infection.
* History of prior hematopoietic stem cell mobilization.

Where it's running

• Dongyang People's Hospital
  Dongyang, Zhejiang, China Recruiting
• The Affiliated Hangzhou First People's Hospital
  Hangzhou, Zhejiang, China Recruiting
• The First Affiliated Hospital, College of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting
• Tongde Hospital of Zhejiang Province
  Hangzhou, Zhejiang, China Recruiting
• Huzhou central hospital
  Huzhou, Zhejiang, China Recruiting
• The First Hospital of Jiaxing
  Jiaxing, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Peipei Ye — The Affiliated People's Hospital of Ningbo University
• Study coordinator: Peipei Ye
• Email: 39612903@qq.com
• Phone: 86-13685832706

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BEX101 CAR-T at the bedside for relapsed or refractory B-cell NHL

  A bedside, on-site CAR-T therapy called BEX101 is being tested in adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma to see if it is safe and can help control the disease.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07882641

• KSVCBD Injection for B-cell Non-Hodgkin's Lymphoma with CD19 and/or BCMA

  This study tests KSVCBD, a CAR-T therapy made inside the body, in adults with relapsed or refractory B-cell non-Hodgkin's lymphoma to see if it is safe and can help fight the cancer.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07620314

• Comparing antibiotics and immunoglobulin to prevent infections in blood cancers

  This project tests whether immunoglobulin or antibiotic strategies better prevent infections in adults with blood cancers.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202052

• Comparing two regimens for mobilizing stem cells in multiple myeloma patients

  This study is testing whether a new combination of medications can help newly diagnosed multiple myeloma patients collect enough stem cells more effectively than a standard treatment.

  Recruiting at 16 sites Phase 3 The Affiliated People's Hospital of Ningbo University · Dongyang, Zhejiang and 15 other locations · NCT06520176

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

• CLIC-2201 treatment for relapsed B cell cancers

  This study is testing a new CAR-T cell therapy called CLIC-2201 to see if it can help people with relapsed B cell cancers feel better and improve their treatment outcomes.

  Recruiting at 7 sites Phase 1 British Columbia Cancer Agency · Calgary, Alberta and 6 other locations · NCT06208735

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.